NCT07041606Recruiting
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
Multicenter, Observational, Prospective Study of Molecular Profiling in Advanced and Aggressive Endometrial Cancer Patients and 1-st Line Treatment Approaches in Russian Federation
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 6 Jun 2025
- Start date
- 24 Jun 2025
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Endometrial cancer
- NCT number
- NCT07041606
What you commit to
- Study type: Observational
- Planned participants: 500
- From 24 Jun 2025 to the primary completion date, 30 Jun 2027
- 19 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Patients participating in clinical (interventional) studies since the diagnosis of histologically confirmed, advanced EC.
Who the study is looking for
- Female patients aged ≥ 18 years old;
- Signed ICF, including consent for archival FFPE tumor tissue block testing;
- Newly diagnosed, histologically confirmed, advanced (III-IV stage) EC, with the date of diagnosis of histologically confirmed disease within 4 months before inclusion;
- Endometrioid type G3 or any non-endometrioid histological type of EC (such as serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated and dedifferentiated carcinoma, carcinosarcoma, others);
- The presence of biopsy or postoperative archival FFPE tumor sample (block);
- Availability of source medical documentation.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (19)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.